Sponsors / ARMP
ARMP

Armata Pharmaceuticals, Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
1Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa InfectionNCT05616221ARMPPhase 2Completed2024-07-17Actual

Latest recorded trial changes

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT05616221 · Armata Pharmaceuticals, Inc.

· 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: P. aeruginosa recovery in sputum following multiple doses of AP-PA02 administered by inhalation

+ Updated value

measure: P. Aeruginosa Recovery in Sputum Following Multiple Doses of AP-PA02 Administered by Inhalation

The saved outcome text may be shortened. Check the source for full wording.

Check registry source